Cardiovascular Risk Reduction in High-Risk Patients Through Lipid Management

PROGRAM DESCRIPTION In this video webcast of a satellite symposium held during the National Lipid Association’s Fall Clinical Lipid Update 2017, Peter Howard Jones, MD, and Joseph J. Saseen, PharmD, ...

PROGRAM DESCRIPTION
In this video webcast of a satellite symposium held during the National Lipid Association’s Fall Clinical Lipid Update 2017, Peter Howard Jones, MD, and Joseph J. Saseen, PharmD, provide their insights into the evolving lipid management of patients at high risk for cardiovascular events. To better facilitate the integration of recent data into real-world clinical practice, Drs. Jones and Saseen discuss 4 case scenarios of patients at different levels of cardiovascular risk. There is no fee for this activity.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:Discuss real-world implications of new data on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsExplain the effect of PCSK9 inhibition in specific clinical scenarios (eg, diabetes, familial hypercholesterolemia, statin intolerance)Identify patients who may benefit from the use of PCSK9 inhibitors―either as monotherapy or in combination with a statin―in order to optimally reduce the risk for atherosclerotic cardiovascular disease (ASCVD)Evaluate lipid management treatment plans to reduce ASCVD risk in patients at particularly high risk

---

Write the first review

Resource tags